BioavailabilityPhase 1NCT00800475
Bioequivalence Study Between Two Oral Formulations of Gemfibrozil Tablets
A Phase 1 study testing Gemfibrozil Tablets in people with Bioavailability, run by Blu Caribe.
Trial summary
The purpose of this study is to determine whether two oral formulations of Gemfibrozil Tablets are bioequivalent. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Bioavailability
- What is being tested?
- Gemfibrozil Tablets
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- No sites listed yet
- Study dates
- Jul 2005to Sep 2005
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- healthy men or women 18 years of age or older
- weight within +/- 20% for height and body frame
- willing to participate and sign a copy of the informed consent form
Who cannot join
- recent history of drug or alcohol addiction or abuse
- pregnant or lactating women
- history of allergic response to gemfibrozil
- use of tobacco products
- evidence of a clinically significant disorder or whose laboratory results were deemed to be clinically significant
- receipt of any drugs as part of a research study within 28 days prior to study dosing
About this study
Official title: A Relative Bioequivalence Study of 600 mg Gemfibrozil Tablets Under Fasting Conditions
The purpose of this study is to determine whether two oral formulations of Gemfibrozil Tablets are bioequivalent.
- Conditions
- Bioavailability
- Being tested
- Gemfibrozil Tablets
- Keywords
- bioavailability, Gemfibrozil
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Gemfibrozil TabletsDrug
| Study group | Role | What they receive |
|---|---|---|
| Test Drug | Active comparator | Not described Receives: Drug: Gemfibrozil Tablets |
| Reference Drug | Active comparator | Not described Receives: Drug: Gemfibrozil Tablets |
What is being measured
The primary outcome is the main question the study is designed to answer.
Bioequivalence was assessed on the pharmacokinetic variables, Cmax, AUCO-t and AUCO-infinity
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Dec 2008 (estimated)
- Study startJul 2005
- Primary completionJul 2005
- Study completionSep 2005
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for BioavailabilityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Blu Caribe
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00800475
- Sponsor's protocol ID
- R05-0116
- Status last verified
- Aug 2013
- First submitted
- 26 Nov 2008
- Last updated
- 13 Aug 2013
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Aug 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Relative Bioequivalence Study of 600 mg Gemfibrozil Tablets Under Fasting Conditions
- ClinicalTrials.gov ID
- NCT00800475
- Acronym / sponsor ID
- R05-0116
- Conditions
- Bioavailability
- Keywords
- bioavailability, Gemfibrozil
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Blu CaribeIndustry (pharma, biotech, devices)
- Study start
- Jul 2005
- Primary completion
- Jul 2005 (actual)
- Study completion
- Sep 2005 (actual)
- First posted
- 2 Dec 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine whether two oral formulations of Gemfibrozil Tablets are bioequivalent.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Test Drug | Active comparator | Drug: Gemfibrozil Tablets |
| Reference Drug | Active comparator | Drug: Gemfibrozil Tablets |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- healthy men or women 18 years of age or older
- weight within +/- 20% for height and body frame
- willing to participate and sign a copy of the informed consent form
Key exclusion criteria (6 listed)
- recent history of drug or alcohol addiction or abuse
- pregnant or lactating women
- history of allergic response to gemfibrozil
- use of tobacco products
- evidence of a clinically significant disorder or whose laboratory results were deemed to be clinically significant
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Gemfibrozil Tablets | Drug | Reference Drug, Test Drug |
Primary outcome
Bioequivalence was assessed on the pharmacokinetic variables, Cmax, AUCO-t and AUCO-infinity
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Aug 2013.
Related trials for Bioavailability
Not yet recruitingPhase 1
Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations After Multiple Doses
Obesity, Overweight
Not yet recruitingPhase 1
Pharmacokinetics and Relative Bioavailability of Intranasal vs Intramuscular Olanzapine in Healthy Adult Participants
Healthy Adult Participants
Active, not recruitingPhase 1
A Comparative Study to Investigate the Difference in Blood Levels of Two Different Formulations of GSK5784283
Asthma
Not yet recruitingPhase 1
A Study of Imlunestrant (LY3484356) in Healthy Female Participants
Healthy
Active, not recruitingPhase 4
Tacrolimus C:D Ratio Measured in Renal Transplant Recipients Treated With Once-daily Prolonged-release Drugs
Immunosuppression
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Gemfibrozil Tablets in people with Bioavailability, run by Blu Caribe.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Aug 2013. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Bioequivalence was assessed on the pharmacokinetic variables, Cmax, AUCO-t and AUCO-infinity. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Aug 2013.